Core Viewpoint - Bayer has received approval from the U.S. Food and Drug Administration for its drug aimed at providing relief for menopause symptoms [1] Group 1 - The FDA approval marks a significant milestone for Bayer in the women's health sector [1] - This drug is expected to address a critical need for menopause relief among women [1] - The approval may enhance Bayer's market position and drive revenue growth in the healthcare segment [1]

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.1 Inhibition of Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons can mod. ...

李英富博士系海博为药业创始人，董事长，拥有近30年药物研发及管理经验，曾在拜耳集团的德国总部 药物研究中心、日本研究中心、美国研究中心从事新药研发10多年，是多个1类临床新药的第一发明人 和项目总负责人。 海博为药业成立于2019年1月，是一家专业从事创新药研发的高成长性高新技术企业。公司法定代表人 为李英富，注册资本716.42万元。 瑞财经 刘治颖 近日，成都海博为药业有限公司（简称"海博为药业"）宣布成功完成逾2亿元B轮融资。 本轮融资由华盖资本领投，元生创投、道远资本、磐霖资本等机构跟投，老股东信成基金持续加码。浩 悦资本担任本轮融资的独家财务顾问。 海博为药业拥有员工近百名，其中研发人员占比80%以上。公司布局10余条具有差异化竞争优势的创新 药研发管线，覆盖肿瘤耐药、肿瘤免疫、疼痛、中枢神经系统、自身免疫系统、真菌感染等多个药物需 求迫切的治疗领域。 本轮融资资金将主要用于海博为药业重磅创新药HBW-004285、HBW-012336、HBW-012462、HBW- 3220、HBW-3210的临床研究及多条临床前创新药研发管线的深入推进。 天眼查显示，海博为药业实际控制人为李英富，控制55.64 ...

在孕妇叶酸市场常年霸榜的爱乐维，正试图将孕期积累的品牌信任延伸至儿童健康赛道。北京商报记者 调查发现，该品牌已在中国市场推出面向3岁以上儿童的护眼酪，正式进入儿童叶黄素领域。爱乐维推 出的护眼酪规格为32粒/盒，售价269元，定价明显高于绝大部分头部企业的同类产品。市场表现方面， 该产品在京东"婴童叶黄素热卖榜"中仅排名第23位，与头部品牌"已售100万+"的销量差距显著。 不仅叶黄素，从去年起，爱乐维也开始在社交平台力推儿童和婴幼儿液体钙。从孕产营养品牌转型为儿 童市场新入局者，爱乐维能否凭借品牌信任克服产品线与市场认知的不足，将成为其新品能否立足的关 键。 关于产品质地，淘宝商品页面标注"非软糖"，但未进一步说明具体形态。淘宝"Elevit爱乐维海外旗舰 店"客服人员表示，该产品类似软糖，可咀嚼但不含糖。该客服人员称，由于是纯进口商品，该产品未 获得"蓝帽子"认证，因此属于营养膳食补充剂，不属于药品或保健品。 医药行业分析师朱明军认为，在竞争激烈的儿童护眼产品市场中，如何清晰传达产品优势，打消消费者 对产品质地和资质的疑虑，将是爱乐维护眼酪需要面对的重要问题。 在成分方面，爱乐维护眼酪强调三大特点：无糖、 ...

常年霸榜孕妇叶酸市场头部地位的爱乐维，正试图将孕期积累的品牌信任延伸至儿童健康赛道。北京商 报记者调查发现，该品牌已经在中国市场推出面向3岁以上儿童的护眼酪，正式进入儿童叶黄素领域。 爱乐维推出的护眼酪规格为32粒/盒，售价269元，定价明显高于绝大部分头部企业的同类产品。市场表 现方面，该产品在京东"婴童叶黄素热卖榜"中仅排名第23位，与头部品牌"已售100万+"的销量差距显 著。不仅是叶黄素，从去年起，爱乐维也开始在社交平台力推自己的儿童、婴幼儿液体钙。从孕产营养 品牌转型为儿童市场新入局者，爱乐维能否凭借品牌信任克服产品线与市场认知的不足，将成为其新品 能否立足的关键。 三天内500+人加购 爱乐维®儿童护眼酪 实力守护眼健康 酮方灵感源自诺贝尔获奖成果4 随着儿童护眼需求日益突出，爱乐维近期推出儿童护眼酪，进入儿童叶黄素市场。该产品明确面向3岁 以上儿童，已在淘宝、京东、小红书等平台的官方跨境店铺上架。 关于产品质地，淘宝商品页面标注"非软糖"，但未进一步说明具体形态。淘宝"Elevit爱乐维海外旗舰 店"客服表示，该产品类似软糖，可咀嚼，但不含糖。客服还指出，由于是纯进口商品，该产品未获 得"蓝帽子 ...

Core Insights - Bayer, in collaboration with Kumquat Biosciences, has initiated a phase I study for KQB548, targeting KRAS G12D-mutated tumors, which include pancreatic, colorectal, and lung cancers [1][7] - The study aims to evaluate the safety and preliminary efficacy of KQB548 as a monotherapy, addressing a significant unmet medical need as current treatments for KRAS G12D mutations are lacking [2][7] Bayer's Pipeline and Market Performance - Bayer's shares have increased by 62.5% year-to-date, significantly outperforming the industry average rise of 7.9% [4] - The company is expanding its pipeline through acquisitions, including BlueRock for cell therapy and AskBio for gene therapy, focusing on various diseases such as retinal disorders and Parkinson's [5] - Bayer's key drugs, Nubeqa and Kerendia, are driving growth in its Pharmaceuticals division, compensating for declining sales of Xarelto [8] Future Drug Developments - Bayer plans to expand the labels of Nubeqa and Kerendia, which could further enhance growth [9] - The company is set to launch two new drugs in 2025: elinzanetant for menopause symptoms and acoramidis for a specific heart disease [9][10] - Elinzanetant has already received approval in the UK and Canada for treating moderate-to-severe menopause-related symptoms [9] Market Position - Bayer currently holds a Zacks Rank of 1 (Strong Buy), indicating a favorable market position [11]

中新网上海10月9日电(记者陈静)第八届中国国际进口博览会(简称：进博会)开幕进入倒计时。进博 会"全勤生"花王、拜耳向记者剧透今年进博会的亮点。 记者9日获悉，作为连续八年参展的"全勤生"，花王今年将携本土化创新产品等亮相进博会。花王方面 表示，八年参展，花王不是在"重复赴约"，而是在"共同成长"。 在作物科学领域，拜耳把"全球智慧+本土创新"深度融入中国农业高质量发展进程，带来7个"中国首 展"和8个"进博会首展"。据透露，在拜耳种业展台上，玉米种子新品牌及九大玉米种子新品种将亮相， 多款蔬菜种子和多个全球研发创新成果也将同步展出。拜耳首度展示在华布局的第三家再生农业示范农 场——吉林梨树耘远农场。 拜耳方面表示，愿以进博会为支点，把握中国机遇，汇聚全球创新，助力中国民众创造美好生活。(完) （文章来源：中国新闻网） 在今年进博会上，花王旗下品牌将携诸多新品登场；除了新品首秀，本届进博会上，花王将首设VIC展 区(Value Innovation Center)，通过消费者共创开发逻辑、跨界合作等四大板块，全面呈现花王138年来 对"清洁、美丽、健康"生活的初心与创新实践。今年，花王首次将ESG主题发布会 ...

Key Takeaways BlueRock posted 36-month data showing bemdaneprocel remains well tolerated in Parkinson's patientsF-Dopa imaging suggests that transplanted cells survived and engrafted after immunosuppression ended. High-dose patients saw a 17.9-point MDS-UPDRS motor score drop, showing clinically meaningful progress.Bayer AG’s (BAYRY) wholly owned, independently operated subsidiary BlueRock Therapeutics LP announced positive 36-month data from an early-stage study of bemdaneprocel, an investigational cell th ...

Core Insights - Pfizer has entered a significant agreement with the Trump administration to reduce drug prices and enhance U.S. innovation and manufacturing [1][2] - The deal includes price reductions for certain drugs to match costs in comparable developed countries and offers substantial discounts through a new purchasing platform [1][2] - Pfizer will receive a three-year exemption from tariffs on pharmaceutical imports in exchange for increasing U.S. manufacturing investment, committing an additional $70 billion [2] Drug Pricing and Tariff Concerns - Trump's Most Favored Nation (MFN) pricing policy aims to ensure U.S. consumers pay the same prices for prescription drugs as in other developed nations, raising concerns about potential negative impacts on drug prices and reimbursements [3] - The Trump administration had previously threatened tariffs as high as 250% on pharmaceutical imports to encourage U.S. production [4] Market Reaction and Investor Sentiment - The Pfizer-Trump deal has positively impacted stock prices of major pharmaceutical companies like Merck, AstraZeneca, AbbVie, and Eli Lilly, as they may pursue similar agreements [5] - The deal, along with increased M&A activity, has improved investor outlook for the pharma sector, which has faced challenges due to tariff and pricing fears [6] - The SPDR S&P Biotech ETF has risen 9.2% in a month and 15.1% year-to-date, while the Large Cap Pharma sector has increased 8.4% in a month and 8.1% year-to-date [6] Company-Specific Developments - Johnson & Johnson (J&J) is experiencing growth in its Innovative Medicine unit despite challenges, with key products driving continued growth [13][16] - Bayer's Pharmaceuticals division is benefiting from strong sales of key drugs like Nubeqa and Kerendia, with plans for new drug launches in 2025 [10][11] - Novartis has shown strong performance with a diverse drug portfolio and is focusing on gene therapy, although it faces challenges from generic competition [18][19] Stock Performance and Earnings Estimates - Bayer's shares have increased by 65.5% this year, with earnings estimates for 2025 rising from $1.28 to $1.33 [12] - J&J's stock has risen 30.6% year-to-date, with earnings estimates for 2025 increasing from $10.62 to $10.86 [17] - Novartis's stock has risen 35.2% this year, with earnings estimates for 2025 increasing from $8.92 to $9.03 [20]

ORLANDO, Fla.--(BUSINESS WIRE)-- #BiotechNews--Hesperos, Inc. (Hesperos), a global leader focused on improving preclinical drug development, food, cosmetic, and chemical testing with its Human-on-a-Chip® (HoaC) single- and multi-organ systems platform, is pleased to announce the publication of a new peer- reviewed study, developed in collaboration with Bayer Consumer Health. The study introduces the first human- relevant microphysiological system (MPS) capable of modeling central nervous system (CNS) stress ...